Shares of vaccine companies fell on Tuesday after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead ...

The Senate Finance Committee advances the nomination of Robert F. Kennedy Jr. for HHS Secretary amid a party-line vote. Read ...

BofA lowered the firm’s price target on BioNTech (BNTX) to $147 from $150 and keeps a Buy rating on the shares. On the Q4 call, the firm will ...

The U.S. Senate Finance Committee has voted to advance Robert F. Kennedy Jr.’s nomination for Secretary of Health and Human ...

Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platformfor the ...

"Pfizer just released its list of side effects of its COVID-19 vaccine," multiple Facebook posts said Jan. 26 and 27. The posts included a purported list of 46 Pfizer-BioNtech COVID-19 vaccine side ...

BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...

According to Benzinga Pro, BioNTech's peer group average for short interest as a percentage of float is 5.26%, which means ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

BioNTech stock is a steal with a low enterprise value and promising pipeline. D.R. Horton looks especially cheap relative to its strong growth prospects. Energy Transfer is a bargain that comes ...

BNT-113 is under clinical development by BioNTech and currently in Phase II for Penile Cancer. According to GlobalData, Phase II drugs for Penile Cancer does not have sufficient historical data to ...